In summary, these discoveries indicate that T cells in ovarian cancer, whether CD4+ or CD8+ T cells, exhibit an extraordinary capacity to activate the formation of TLS through the release of the chemokine CXCL13 and coordinate the anti-tumor immune response, thereby potentially strengthening the body’s defense mechanisms against cancer. Here, CD8A is linked to ovarian carcinoma.